PROVIDER PROFILE · NPI 1306049010

Molly MenserD.O.

DermatologyRiverside, MOI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

507

Unique beneficiaries

—

Total services

687

Distinct HCPCS

Medicare payment

$36K

Peer benchmark

Total Medicare services vs. 207 Dermatology providers in MO — below median (cohort median 3,056).

PRESCRIBING · PART D · 2024

Total Rx claims

416

Beneficiaries

—

Total drug cost

$8K

Distinct drugs

Brand share

12.5%

Top prescribed drugs

Triamcinolone Acetonide68 claims

Clobetasol Propionate59 claims

Minoxidil58 claims

Hydrocortisone46 claims

Ketoconazole33 claims

QUALITY · MIPS · 2024

Final MIPS score

88.8

Quality

80.3

Cost

82.5

Improvement activities

40.0

Promoting interop.

100.0

Payment adjustment

0.58%

Group

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$2K

Payment records

By payment type

Food and Beverage$2K

REFERRAL NETWORK

Where Molly Menser's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 2 inbound referrers · 5 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Mawd Pathology Group Pa Clinical Laboratory · Lenexa, KS	89	224
Nicholas Rudloff Dermatology · Riverside, MO	12	79

Refers patients to

Outbound — where patients go next

Physician	Patients	Visits
NORTH KANSAS CITY HOSPITAL	32	57
Labone Llc Clinical Laboratory · Lenexa, KS	29	45
Mawd Pathology Group Pa Clinical Laboratory · Lenexa, KS	21	47
Nicholas Rudloff Dermatology · Riverside, MO	21	106
Brian Matthys Dermatology · Riverside, MO	20	68

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history